Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus PATHILON.
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol sulfate is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
2 inhalations (each inhalation delivers 90 mcg albuterol sulfate and 18 mcg ipratropium bromide) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
Albuterol: terminal half-life 3.8-6 hours; Ipratropium: terminal half-life 1.5-4 hours (clinical: twice-daily dosing for chronic therapy).
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Albuterol: renal excretion of unchanged drug and metabolites (~60-70% as metabolites, ~10-20% unchanged); Ipratropium: primarily renal (~50% unchanged), with biliary/fecal excretion accounting for minor amounts.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category A/B
Category C
Anticholinergic
Anticholinergic